Emerging hematological targets for cardiovascular disease
=========================================================

Historical development
----------------------

Cardiovascular disease is the leading cause of death and disability ([@b39-btt-2-397]). In the last years of the 20th century the role of inflammation in atherosclerosis was widely recognized ([@b126-btt-2-397]), according to previous hypotheses ([@b147-btt-2-397]).

Nevertheless, a mere tissue and innate immunity-mediated response to local inflammation did not fit several observations. First was the coincidence of different atherosclerotic locations (coronary, aortic, carotid), at a simultaneous degree of evolutionary state ([@b59-btt-2-397]). Second was the the growing concern of accelerated atherosclerosis in autoimmune diseases ([@b137-btt-2-397]), which highlighted the importance of acquired immunity in this vascular disorder ([@b57-btt-2-397]). The third event was the discovery of bone-marrow derived progenitor cells that were able to differentiate towards the endothelial lineage in animal models ([@b5-btt-2-397]) and humans ([@b145-btt-2-397]), being the medical importance of these progenitors an emerging matter of interest ([@b64-btt-2-397]).

Soluble inflammatory mediators in atherosclerosis
-------------------------------------------------

The approach of atherosclerosis as an inflammatory disease led to the search of inflammatory markers (reviewed in [Table 1](#t1-btt-2-397){ref-type="table"}). Several of these molecules include: interleukin (IL)-1 ([@b70-btt-2-397]), IL-ra ([@b127-btt-2-397]), tumor necrosis factor (TNF) ([@b104-btt-2-397]), IL-6 ([@b82-btt-2-397]), and monocyte chemotactic protein-1 (MCP-1) ([@b62-btt-2-397]). However, although these markers seem to be elevated in atherosclerotic patients compared to disease-free controls, their lack of specificity seems to be the most important limitation.

In atherosclerosis, a misbalance between T-helper-1/T-helper-2 (Th1/Th2) function seems to take place ([@b141-btt-2-397]). Th1 function (mediated by the cytokines interferon (IF)-γ, TNF-α) is regarded as proatherogenic, whereas Th2 (mediated by IL-4, IL-5) is considered as protective ([@b57-btt-2-397]). Balance is mediated by Th3 function, which may regulate transition from Th1 to Th2 by the cytokines IL-10 and tumor growth factor (TGF)-β1 ([@b118-btt-2-397]). However, although serum levels of active and total fraction of TGF-β1 have been related to both the protection against an acute coronary event ([@b51-btt-2-397]) and the development of chronic atherosclerosis lesions ([@b84-btt-2-397]), the implementation of blood levels of TGF-β1 for atherosclerosis diagnosis has remained elusive ([@b118-btt-2-397]).

Among all biochemical blood inflammatory markers for atherosclerosis, C-reactive protein (CRP) has been studied deeply ([@b121-btt-2-397]). This protein is secreted by the liver in response to serum IL-6 and activated from pentameric to monomeric on the vessel wall, where it enhances inflammatory cell recruitment, platelet adhesion and thrombosis ([@b76-btt-2-397]). Large clinical evidence linked blood levels of high-sensitivity measured CRP as an independent marker for subclinical atherosclerosis ([@b142-btt-2-397]), cardiovascular disease severity ([@b10-btt-2-397]), and the coming of future cardiovascular events ([@b18-btt-2-397]; [@b10-btt-2-397]). However, more recent clinical evidence subsequently showed the limitations of this marker as an independent risk factor ([@b41-btt-2-397]; [@b153-btt-2-397]; [@b93-btt-2-397]).

Leukocytes
----------

White cell count has been established as an independent marker of subclinical atherosclerosis ([@b134-btt-2-397]). Moreover, this widely available parameter may be a sensitive predictor of the coming of future coronary events ([@b54-btt-2-397]) and long-term mortality ([@b107-btt-2-397]).

The role of leukocytes in atherosclerosis was first recognized for the monocyte/macrophage lineage. Pathologic specimens have always shown the accumulation of macrophages in the extreme zone of atherosclerotic lesions (the plaque shoulder), which make them more prone to rupture and thrombosis ([@b48-btt-2-397]). These inflammatory macrophages are positive for CD36^+^, a scavenger receptor which facilitates the uptake of small and dense oxidized low-density lipoprotein (LDL) particles and gives them the appearance of foam cells ([@b98-btt-2-397]). These foam cells become inflammatory enhancers, which precipitate the plaque instability ([@b79-btt-2-397]). Circulating monocytes, the blood precursors of macrophages, have also been implicated in atherosclerosis. Clinical whole monocyte count precedes the coming of coronary ([@b97-btt-2-397]) and cerebrovascular ([@b74-btt-2-397]) events, as well as subclinical carotid stenosis ([@b23-btt-2-397]). Moreover, a direct correlation has been found for monocyte count and infarct size ([@b99-btt-2-397]). Monocyte concentration has equally been inversely correlated to eventual ejection fraction after ischemia ([@b96-btt-2-397]). After coronary artery bypass grafting these monocytes lose the membrane receptor CD14^+^ and secrete soluble CD14^+^ to plasma, a general mechanism in monocyte activation ([@b40-btt-2-397]).

Another leukocyte type with emerging importance in atherosclerosis is the lymphocyte, since a significant accumulation of lymphocytes has been reported in histological studies ([@b48-btt-2-397]). They are mostly T cells (CD3^+^), with helper function (CD4^+^) which participate in plaque instability by secretion of cytokines, specially associated with the Th1 phenotype ([@b58-btt-2-397]). In order to regulate this atherogenic immune response, several experimental attempts in animal models have been made with vaccines to induce antibodies secretion and further elimination of oxidized LDL ([@b17-btt-2-397]), or immunological tolerance for HSP65 ([@b56-btt-2-397]).

An increasing amount of experimental and clinical evidence highlights the importance of neutrophils in atherosclerosis. Neutrophils have been shown to predict clinical coronary stenosis ([@b7-btt-2-397]). These clinical observations have been reproduced in experimental conditions. In the apoE-/- mice model, disruption of the SDF/CXCR4 by the drug AMD3100 increased bone marrow production, blood levels and atherosclerotic infiltration of neutrophils, an event which was able to be prevented by anti-neutrophil antibody injection ([@b157-btt-2-397]).

Red blood cells
---------------

Red blood cells (RBC) precipitate intraplaque hemorrhage, which leads to plaque instability. Large extracellular cholesterol crystals in unstable atherosclerotic plaques come from the membrane cholesterol of senescent RBC after intraplaque hemorrhage ([@b78-btt-2-397]). Circulating RBC are able to dampen vessel oxidative damage by means of their antioxidant machinery (glutathione), a physiological role closely related to their ability to uptake, carry and release nitric oxide (NO), thus enhancing local vasodilation and prevention of ischemia ([@b101-btt-2-397]). However, when local inflammatory and oxidative stimulus is strong enough to surpass their capability, RBC behave as "oxidative bullets", extending the oxidative damage by ONOO- transport ([@b30-btt-2-397]). Ischemic and oxidative damage to RBC increases membrane phosphatidylserine ([@b135-btt-2-397]), become aggregated among them (an event mediated by fibrinogen) and to the surrounding endothelium (mediated by thrombospondin) ([@b101-btt-2-397]). RBC damage and loss of their physiological antioxidant and anti-ischemic role is a frequent complication of unstable hemoglobin conditions, such as sickle cell disease and thallassemia, where there is a vicious circle between RBC dysfunction and ischemia ([@b117-btt-2-397]).

Extracorpuscular hemoglobin is able to behave as a powerful proinflammatory and oxidative factor. Extracorpuscular hemoglobin can be inactivated by haptoglobin (Hp). Interestingly, Hp genotype may mediate the extent of this protective response. The Hb1 allele may exert a protective role in atherosclerosis whereas the Hb2 allele is associated to increased infarct size in diabetic patients and a poorer response to antioxidant therapy ([@b88-btt-2-397]).

Hemostatic factors
------------------

Hemostasis is closely related to macrophage-mediated inflammation, since oxidized LDL is able to increase macrophage apoptosis by the caspase-3 pathway, wich eventually triggers tissue factor activation and initiation of the extrinsic coagulation cascade ([@b69-btt-2-397]). Thus, the capability of an atheromatous plaque to become clinically significant seems to be closely correlated to its thrombotic capability rather than the mere mechanical disruption. Therefore, current nomenclature highlights the concept high-risk plaque rather than fragile plaque ([@b48-btt-2-397]), since thrombosis is a key issue not only from the high-risk atheromatous plaque but also from the blood of the whole high-risk patient ([@b28-btt-2-397]). Type 2 diabetes mellitus increases the inflammatory and pro-coagulant state of the blood when it passes through a Badimon chamber ([@b111-btt-2-397]). Hypercholesterolemia, especially when associated with small, dense and oxidized LDL particles, is equally able to increase blood coagulability *in vitro* ([@b2-btt-2-397]) and *in vivo* ([@b9-btt-2-397]). Statins are able to decrease the procoagulant trend in atherosclerotic patients ([@b75-btt-2-397]).

Tissue factor is up-regulated in atherosclerosis ([@b47-btt-2-397]), especially in areas of plaque rupture ([@b29-btt-2-397]). In cell culture experiments, a wide variety of *in vitro* atherosclerotic putative triggers (CRP, cholesterol esters, glucose, angiotensin) are able to increase the acivity of tissue factor in cultured macrophages and vascular smooth muscle cells ([@b25-btt-2-397]), an event prevented by *in vitro* incubation with anti-atherosclerotic drugs, such as statins ([@b32-btt-2-397]) and antiplatelet drugs ([@b22-btt-2-397]). Blood fibrinogen is also closely related to atherosclerosis, since it is triggered by IL-6 ([@b94-btt-2-397]) and correlated to artery occlusion ([@b108-btt-2-397]).

Platelets are involved in the atherosclerotic process. They form the first hemostatic defense; therefore they initiate and trigger the atheromatous instability ([@b48-btt-2-397]). This fact may explain the benefits of antiplatelet drugs in the secondary prevention of myocardial infarct and unstable angina ([@b3-btt-2-397]). Aspirin inhibits plaque aggregation by irreversible acetylation of Ser530 of COX-1 ([@b8-btt-2-397]). Clopidogrel inhibits platelet function by inhibition of ADP receptor. These two antiplatelets can be combined ([@b4-btt-2-397]). However, current evidence-based indications of combined therapy have not been established in the prevention of cardiovascular events ([@b15-btt-2-397]) and are restricted to the post-stent situation ([@b14-btt-2-397]) and when a lone drug proves unable to achieve clinical success ([@b35-btt-2-397]). Related to this, the concept of "aspirin resistance" has emerged in recent years. It may be referred as this lack of clinical antiplatelet control (clinical aspirin resistance), persistence of high platelet activity (*in vitro* resistance) or persistence of elevated serum or plasma markers of platelet activity (resistance measured as surrogate markers) (Michelson et al 2005). Aspirin resistance (measured as the urinary concentration of thromboxane) has been shown to be an independent cardiovascular risk factor ([@b37-btt-2-397]).

Increased platelet activity may trigger endothelial damage ([@b106-btt-2-397]). This vascular pro-inflammatory role for the platelets is played by their secretory granules, which secrete chemokines for leukocyte adhesion ([@b151-btt-2-397]), platelet-derived growth factor (PDGF) as a potent growth factor for vascular smooth muscle cells ([@b81-btt-2-397]) and TGF-β1. TGF-β1 is an antiinflammatory cytokine which seems to lose this physiological role in atherosclerosis, where it becomes profibrotic and possibly induces vascular progenitor differentiation towards the smooth muscle lineage ([@b118-btt-2-397]).

Vascular progenitors
--------------------

Although the existence of a unique progenitor for blood and vessel cells (the hemangioblast) has classically been accepted in embryos, the extension of this concept to adult animals took place in 1997 ([@b5-btt-2-397]). Further studies in human beings determined the importance of these progenitors in vascular self-repair. Endothelial progenitor cells (EPCs) are originated in the bone marrow, from CD34+ stem cells ([@b64-btt-2-397]). Enzyme disruption from the stromal cell-derived factor-1 (SDF-1)-rich matrix by matrix metallopeptidase 9 (MMP-9) releases c-kit ligand and allows the exit of these cells from the bone marrow, a process which requires a sufficient blood, vascular and oxygen supply ([@b65-btt-2-397]). Early EPCs are positive for several markers, such as CD34+, CD133+, and KDR+. Early EPCs circulate in blood, home to the denuded endothelium, differentiate to endothelial cells (a process where they acquire CD144+ and vVW+) and thus repopulate the endothelium or secrete local paracrine factor to increase the physiological state of resident cells ([@b73-btt-2-397]; [@b11-btt-2-397]). The homing of these cells is regulated by several chemokines such as CXCR4 ([@b67-btt-2-397]).

The first *in vitro* characterizations of putative EPCs were done by uptake of acetylated low density lipoprotein and *Ulex europaeus* lectin binding and these capabilities were shown to be shared by monocytes. This evidence led to some research groups to re-consider the property of the term EPC instead of circulating angiogenic cells ([@b120-btt-2-397]). It may be considered that the heterogeneous EPC progeny evolves from the CD34+ stem cell and acquire monocytic (CD14+) and/or endothelial markers (subsequently CD133+, KDR+, CD144+, and vVW+) ([@b124-btt-2-397]). The role of these cells types is double: first is to patch and re-populate the endothelial layer ([@b110-btt-2-397]; [@b73-btt-2-397]). Second is to behave of tissue stimulators for resident endothelial cells ([@b103-btt-2-397]; [@b120-btt-2-397]; [@b124-btt-2-397]).

Clinical studies show a close correlation between the *in vitro* EPC colony forming units (CFUs) and the *in vivo* endothelial function ([@b60-btt-2-397]). CFU capability, endothelial marker expression and proliferation are dampened when EPCs are incubated with proatherosclerotic triggers (LDL-cholesterol, angiotensin) ([@b71-btt-2-397]; [@b116-btt-2-397]).

Blood levels of EPCs are inversely correlated to Framingham risk factors ([@b145-btt-2-397]) and to the direct angiographic coronary obstruction ([@b80-btt-2-397]). Low EPC count in patients precedes the coming of atherosclerotic events ([@b132-btt-2-397]) and can be increased by statin treatments ([@b33-btt-2-397]; [@b145-btt-2-397]). However, this putative protective role of EPCs is faced by the fact that their number increases after a heart infarct ([@b86-btt-2-397]), although EPC capability to form *in vitro* CFUs remains diminished in patients with coronary heart disease (Liguori et al 2007) and this post-infarct CFU impairment is associated to post ischemic heart failure ([@b77-btt-2-397]). Animal models show an increased atherosclerotic growth when cultured EPCs are infused ([@b49-btt-2-397]). Clinical studies also show a decreased EPC after long-term statin treatment ([@b67-btt-2-397]). Other study shows a direct correlation between angiographic coronary obstruction and EPC number ([@b53-btt-2-397]). In addition, a large and recent population-based study shows a direct correlation between Framingham's risk factors and EPC number; a similar correlation is not found in CFU ([@b154-btt-2-397]). This apparent lack of consensus may be explained by the lack of one unified definition of EPC, based on stem ontogeny, transcription factors and markers ([@b87-btt-2-397]). Another factor to explain this heterogeneity is the dependence on the evolutionary state. In chronic heart failure EPC concentration is increased as a putative defense mechanism against an ischemic insult, although it becomes decreased in more advanced disease states ([@b144-btt-2-397]).

Bone marrow can also produce smooth muscle progenitor cells (SPCs), which may possess the capability to increase intima-media thickness and neointimal restenosis ([@b129-btt-2-397]), although their role in primary atherosclerosis has been shown to be minimal ([@b13-btt-2-397]). Atherosclerotic patients have a higher blood concentration of CD14^+^/CD105^+^ cells, which give raise to SPC in culture ([@b140-btt-2-397]). CD105^+^ or endoglin is an accessory receptor of TGF-β1 which may regulate differentiation towards the smooth muscle lineage ([@b118-btt-2-397]). CD14^+^ is monocyte marker which is shared by a wide variety of vascular progenitors ([@b120-btt-2-397]). An unresolved mystery is whether EPCs and SPCs come from a unique progenitor or come from different circulating early progenitors which may use different adherence systems ([@b62-btt-2-397]; [@b73-btt-2-397]). Related to this, endothelial to mesenchymal transition has been described in mice embryo. Interestingly, in this model endothelial to mesenchymal progress was enhanced by TGF-β1 ([@b156-btt-2-397]).

Emerging hematological therapies for cardiovascular disease
===========================================================

Progenitor cell therapy
-----------------------

Pioneer experimental therapeutic attempts on animal models were able to show that *in vivo* infusion of bone marrow-derived EPCs improved heart and hind limb ischemia. These results suggested that, although a deregulation of EPC function seem to take place in ischemia, artificial self-transplantation may overcome the lack of bone marrow release, blood destruction, lack of adhesion, or abnormal differentiation.

Initial evidence has demonstrated the feasibility and safety of intracoronary infusion of EPCs ([@b125-btt-2-397]). The majority of clinical evidence to date is obtained in trials where bone marrow-derived mononuclear cells were obtained from the patient and intracoronary infusion was made, in addition to the state-of-the-art interventional therapy. A brief description of several of these trials is shown in [Table 2](#t2-btt-2-397){ref-type="table"}. As a whole, a recent systematic review ([@b1-btt-2-397]) and a meta-analysis ([@b66-btt-2-397]) conclude that these interventions are feasible, safe, and associated to a small increase in left ventricular ejection fraction (LVEF). In addition, a recent meta-regression using data from ten studies show a dose-response effect for the infused volume when the ejection fraction is measured ([@b90-btt-2-397]).

Limitations of the current state of the evidence highlight the lack of consensus about the best technical protocol. The vast majority of trials use bone marrow-derive mononuclear cells. However, the best volume to extract is unknown. Several studies have used peripheral blood-derived mono-nuclear cells, although bone marrow material is the leading source in most trials. Nevertheless, bone marrow mononuclear cells include a wide variety of cells beyond EPCs; some of them may differentiate towards a pathogenic direction. As stated by the European Task Force, technical protocols to elucidate the best interventional procedure for progenitor-induced repair are expected to be time and effort-consuming ([@b12-btt-2-397]). A clinical question to be answered is whether intracoronary infusion of EPCs is able to improve clinical outcomes beyond surrogate markers (such as left ventricular ejection fraction \[LVEF\]) for a sustained period of time. As far as mechanistic studies are concerned, the issue to be addressed refers to the exact underlying explanation of EPC-mediated benefit. A low amount of intramyocardial bone marrow mononuclear cells is able to adhere in human series using radiolabelling methods, ranging from 9.2% for bone marrow-derived CD133+ and 6.8% for bone marrow-derived CD133+/CD34+ ([@b50-btt-2-397]) to 5.5% for peripheral blood-derived CD34+ at 1 hour after implantation ([@b20-btt-2-397]). This percentage rises to 6.9%--8% (2 h) and 2.3%--3.2% (12 h) after intracoronary infusion of CD133+ cells after G-CSF mobilization and separation from the peripheral blood ([@b136-btt-2-397]).

Vascular progenitor modulation by current cardiovascular drugs
--------------------------------------------------------------

Statins have been shown to increase the number of CD34+/KDR+ cells in atherosclerotic patients ([@b145-btt-2-397]). This effect seems to involve the stimulation of PI3K-Akt in the bone marrow, which improves microvessel function and subsequent EPC release ([@b33-btt-2-397]). Interestingly, this molecular pathway is uncoupled in the diabetic state ([@b109-btt-2-397]) and may be responsible for the decreased concentration of EPCs in diabetic patients ([@b43-btt-2-397]). More recent clinical evidence showed that long-term and long-dose statin treatment was able to decrease of EPCs (measured as CD34+/KDR+) ([@b67-btt-2-397]). Nevertheless, statin-mediated biphasic effect seems to be associated to a late increase of CD34+/CD144+ EPCs, which show a potential effect of statins on EPC differentiation from early to advanced progenitors ([@b31-btt-2-397]).

Renin-angiotensin system inhibitors have been related to EPC mobilization. *In vivo* infusion of angiotensin II in rats was able to induce decrease of EPC count and telomerase activity, with a subsequent increase of EPC senescence. These effects were inhibited by administration of the AT1-blocker valsartan ([@b71-btt-2-397]). Irbesartan was also associated to increased EPC counts ([@b16-btt-2-397]). Enalapril was found to increase the bone marrow release of early EPC progenitors in a rat model by involving CD26+ (dipeptidylpeptidase) enzyme stimulation, which induces EPC release ([@b149-btt-2-397]).

Thiazolidinediones (rosiglitazone and pioglitazone) are peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists which may possess direct and independent cardiovascular benefits ([@b38-btt-2-397]), although there is a recent concern for potential danger of rosiglitazonemediated heart failure in high-risk patients ([@b91-btt-2-397]). Incubation with rosiglitazone induces *in vitro* endothelial differentiation from a cluster of vascular progenitors ([@b148-btt-2-397]). Pioglitazone has been found to restore the quantitative and qualitative defect (measured as impaired *in vitro* formation of capillaries) which is found in type 2 diabetes patients ([@b149-btt-2-397]). This effect may be mediated by a PPAR-γ-dependent increase of EPC adhesion under flow ([@b118-btt-2-397]). This may explain the increased EPC counts in diabetic ([@b149-btt-2-397]) and nondiabetic patients ([@b152-btt-2-397]) under pioglitazone treatment.

Some antiatherosclerotic drugs have been shown to decrease the proliferation of EPC after *in vitro* incubation. Aspirin has been shown to possess this capability at milimolar concentrations ([@b24-btt-2-397]). This capability is also shared by COX-2 inhibitors ([@b27-btt-2-397]). Rapamycin is a potent *in vitro* inhibitor of EPC growth ([@b72-btt-2-397]), which may mediate the endothelial damage of rapamycincoated stents ([@b158-btt-2-397]). Future research will clear the role of differential progeny, isolation, adhesion and differentiation in these cell culture experiments.

Eventually, the physical activity has been proven to affect EPC number and function. Physical training in mice increased the number of circulating EPCs ([@b83-btt-2-397]) being these results reproduced in patients ([@b138-btt-2-397]). This is related to increased blood levels of VEGF and SDF induced by exercise ([@b128-btt-2-397]). Some results were able to correlate exercise-mediated EPC increase with increased levels of EPO in trained subjects ([@b138-btt-2-397]). Cardiac rehabilitation was equally able to increase EPC CFUs and decrease EPC apoptosis ([@b115-btt-2-397]).

Vascular progenitor modulation by target-designed novel molecules
-----------------------------------------------------------------

Being EPC derived from the hematological stem cells committed towards the myeloid lineage, one of the most intuitive interventions to induce EPC release is granulocyte-colony stimulating factor (G-CSF), a stimulus for myeloid recovery ([@b112-btt-2-397]). Studies on animal models were able to show a G-CSF-mediated increase of circulating CD34+ cells, which was associated to improved angiogenesis and conserved myocardial function ([@b113-btt-2-397]). Treatment with G-CSF treatment was able to increase the blood levels of CD34+ cells in coronary disease patients ([@b139-btt-2-397]) with a related improvement in LVEF ([@b105-btt-2-397]), G-CSF treatment is able to increase CFU capability, although *in vitro* migration remained diminished ([@b61-btt-2-397]). The randomized REVIVAL-2 trial was unable to find a significant change on infarct size, LVEF, or coronary obstruction ([@b160-btt-2-397]). The STEMMI trial was equally unable to find a significant benefit for G-CSF treatment ([@b123-btt-2-397]). Advanced age may dampen the efficacy of G-CSF to increase EPC number and/or function ([@b85-btt-2-397]).

Another approach is the usage of G-CSF to enrich EPC extraction by apheresis, as a purified source of EPCs for therapeutical intracoronary infusion ([@b123-btt-2-397]). However, in addition to the well-known side effects of G-CSF (such as bone pain and influenza-like syndrome), the inflammatory state of atherosclerotic lesions might be increased due to the unspecific release of leukocytes from the bone marrow, with an initial strengthened release of monocytes ([@b114-btt-2-397]).

Another approach to increase EPC release from the bone marrow is AMD3100, a small molecule which antagonizes the binding of SDF and CXCR4. Animal experimental evidence shows a significant increase of CD34+ ([@b21-btt-2-397]), being these results reproduced in human volunteers ([@b89-btt-2-397]; [@b46-btt-2-397]). Nevertheless, caution should be addressed for the implementation of his compound, since it may also inhibit EPC homing from the blood to the denuded vessel ([@b155-btt-2-397]) and increase unspecific leukocyte release, which may increase plaque fragility ([@b157-btt-2-397]).

Another substance to increase EPC number and function is erythropoietin (EPO). In animal experimental ischemia, EPO has been found to possess infarct-limiting effect ([@b102-btt-2-397]) and thus maintain LVEF ([@b133-btt-2-397]). In addition to the direct protective effect for myocytes ([@b55-btt-2-397]), EPO is able to increase EPC blood concentration in mice models of ischemia ([@b143-btt-2-397]). A single bolus of EPO has been shown to increase blood number of EPCs (CD34+/CD45−) in patients with acute myocardial infarction, although LVEF remains the same after four months ([@b92-btt-2-397]).

Current efforts are being made in order to obtain compounds which affect EPC release, adhesion and differentiation in a selective manner. According to this approach, a cGRD (cyclic Arg-Gly-Asp) peptide-coated stent was found to selectively induce EPC adhesion in porcine coronary arteries and inhibit neointimal hyperplasia ([@b19-btt-2-397]).

Vascular implications in hematological malignancies
---------------------------------------------------

Experimental ([@b45-btt-2-397]) and clinical ([@b26-btt-2-397]) evidence showed the therapeutical value of antiangiogenic cancer treatment. In hematological malignancies, multiple myeloma is the paradigm of neoplasic disease where antiangiogenic therapy has been established in the state-of-the-art clinical practice, with thalidomide ([@b42-btt-2-397]) and lenalidomide ([@b34-btt-2-397]). Increased EPC numbers are correlated to the clinical outcome in multiple myeloma, being decreased after thalidomide treatment ([@b159-btt-2-397]). Moreover, a significant population of myeloma patients possesses circulating EPCs which come from the neoplasic clone ([@b122-btt-2-397]).

These results about the clonal (neoplasic) origin of a substantial population of tumor growth-related endothelial cells has equally been found in chronic myelogenous leukemia, where bcrabl protein was found in endothelial cells generated *in vitro* from the bone marrow of six patients ([@b52-btt-2-397]). Further evidence was able to identify a bone marrow chronic myelogenous leukemia progenitor with hemangioblast capability ([@b44-btt-2-397]). Imatinib (bcrabl blocker) may possess some degree of angiogenicrelated mechanism of action, since it has been shown to decrease cell secretion of VEGF in cell culture studies ([@b36-btt-2-397]).

Conclusion and clinical perspective
===================================

Despite the increase in our knowledge of atherosclerosis, cardiovascular mortality remains as the first cause of death. Research on the role of blood and marrow in atherosclerosis may lead to the implementation of novel, independent and specific risk factors for the early diagnose and treatment monitoring. Moreover, current discoveries on the regulation of vascularization and ischemia are expected to generate a rational therapeutical approach to control hematological malignancies.
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###### 

Inflammatory factors at the vessel wall level

  Molecule
  -------------------------------------------------------------------
  IL-1 Initiator of cell adhesion molecule expression
  IL-ra IL-1 receptor antagonist (soluble endogenous inhibitor)
  MCP-1 Monocytic chemo-attracting protein
  TNF-α Induces cell apoptosis, inflammation, and adhesion
  IL-6 Soluble trigger for hepatic CRP release
  IF-γ Interferon gamma, macrophage stimulus
  IL-4 and 5 Typical Th2 cytokines
  IL-10 Th2 inducer
  TGF-β1 Modulates inflammation, cell growth and differentiation
  CRP C-reactive protein, induces endothelium activation
  CD36 Stimulus for cholesterol uptake and foam cell transformation
  HSP65 Heat shock protein, initiator of intracellular inflammation
  SDF Induces stem and inflammatory cell adhesion/migration
  CXCR4 Chemokine family receptor for SDF
  PDGF Potent mitogenic factor for vascular smooth muscle

**Abbreviations:** CRP, C-reactive protein; IF, interferon; IL, interleukin; TGF, tumor growth factor; TNF, tumor necrosis factor; PDGF, platelet-derived growth factor; SDF, stromal-derived factor.

###### 

Some clinical trials about the potential therapeutical role of EPCs

  Study         Reference           Finding
  ------------- ------------------- -------------------------------------------
  TOPCARE-AMI   [@b130-btt-2-397]   8% increase of LVEF after 4 months
  REPAIR-AMI    [@b131-btt-2-397]   2.5% increase of LVEF after 4 months
  BOOST         [@b100-btt-2-397]   Similar LVEF after 18 months
  ASTAMI        [@b95-btt-2-397]    Similar LVEF after 6 months (*p* = 0.054)
  TOPCARE-CHD   [@b6-btt-2-397]     Decreased mortality after 577 days

**Abbreviations:** EPCs, endothelial protector cells; LVEF, left ventricular ejection fraction.
